The association between antiepileptic drug and HMG-CoA reductase inhibitor co-medication and cholesterol management in patients with epilepsy

Epilepsy Research

Volumn 91, Issue 2-3, 2010, Pages 260-266

  Candrilli, Sean D ^a   Manjunath, Ranjani ^b   Davis, Keith L ^a   Gidal, Barry E ^c  

^a RTI HEALTH SOLUTIONS   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Antiepileptic drugs; Cholesterol; Drug interactions; Outcomes; Statins

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMOTRIGINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE CALCULATION; DRUG ANTAGONISM; DRUG CHOICE; DRUG USE; EPILEPSY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CHOLESTEROL, LDL; COHORT STUDIES; DISEASE MANAGEMENT; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77957019361     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2010.07.021     Document Type: Article

References (27)

1. Anderson G.D. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 2004, 23:3-8.
2. Andrade S.E., Kahler K.H., Frech F., Chan K.A. Methods for evaluation of medication adherence using automated databases. Pharmacoepidemiol. Drug Safety 2006, 15:565-574.
3. Cannon C.P., Steinberg B.A., Murphy S.A., Mega J.L., Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J. Am. Coll. Cardiol. 2006, 48:438-445.
4. Cepeda M.S., Boston R., Farra J.T., Strom B.L. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am. J. Epidemiol. 2003, 158:280-287.
5. Charlson M.E., Pompei P., Ales K.L., McKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chron. Dis. 1987, 40:373-383.
6. Fuhr U. Induction of drug metabolizing enzymes: pharmacokinetic and toxicological consequences in humans. Clin. Pharmacokinet. 2000, 38:493-504.
7. Gaitatzis A., Carroll K., Majeed A., Sander W.J. The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia 2004, 45:1613-1622.
8. Gidal B.E., French J.A., Grossman P., Le Teuff G. Assessment of potential drug interactions in patients with epilepsy. Impact of age and sex. Neurology 2009, 72:419-425.
9. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith S.C., Stone N.J. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association, implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
10. Khandwala H.M. Lipid lowering inefficacy of high-dose statin therapy due to concomitant use of phenytoin. South. Med. J. 2006, 99:1385-1387.
11. Kyrkland C., Backman J.T., Kivisto K.T. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther. 2000, 68:592-597.
12. Losina E., Barrett J., Baron J.A., Katz J.N. Accuracy of medicare claims data for rheumatologic diagnoses in total hip replacement recipients. J. Clin. Epidemiol. 2003, 56:515-519.
13. Mialer M. The pharmacokinetics and interactions of new antiepileptic drugs. Ther. Drug Monit. 2005, 27:722-726.
14. Miller J.M., Bullman J.N., Alexander S., VanLandingham K.E. A prospective assessment of the effect of phenytoin on the pharmacokinetics of atorvastatin. Epilepsia 2008, 49:444.
15. Mills E.J., Rachlis B., Wu P., Devereaux P.J., Arora P., Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J. Am. Coll. Cardiol. 2008, 52:1769-1781.
16. Murphy M.J., Dominiczak M.H. Efficacy of statin therapy: possible effect of phenytoin. Postgrad. Med. J. 1999, 75:359-361.
17. Neuvonen P.J., Backman J.T., Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin. Pharmacokinet. 2008, 47:463-474.
18. Newcomer R., Clay T., Luxenberg J.S., Miller R.H. Misclassification and selection bias when identifying Alzheimer's disease solely from medicare claims records. J. Am. Geriatr. Soc. 1999, 47:215-219.
19. Nilsson L., Tomson T., Farahmand B.Y., Diwan V., Persson P.G. Cause-specific mortality in epilepsy: a cohort study of more than 9000 patients once hospitalized for epilepsy. Epilepsia 1997, 38:1062-1068.
20. Patsalos P., Perucca E. Clinically important drug interactions in epilepsy: interaction between antiepileptic drugs and other drugs. Lancet Neurol. 2003, 2:473-481.
21. Poli A. Atorvastatin. Pharmacological characteristics and lipid-lowering effects. Drugs 2007, 67:3-15.
22. Pugh M.J., Van Cott A.C., Cramer J.A., Knoefel J.E., Amuan M.E., Tabares J., Ramsay R.E., Berlowitz D.R. Trends in antiepileptic drug prescribing for older patients with new-onset epilepsy: 2000-2004. Neurology 2008, 70:2171-2178. Treatment In Geriatric Epilepsy Research (TIGER) team.
23. Rosenbaum P.R., Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika 1983, 70:41-55.
24. Sikka R., Xia F., Aubert R.E. Estimating medication persistency using administrative claims data. Am. J. Manag. Care 2005, 11:449-457.
25. Sillesen H., Amarenco P., Hennerici M.G., Callahan A., Goldstein L.B., Zivin J., Messig M., Welch K.M. Stroke prevention by aggressive reduction in cholesterol levels investigators, atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2008, 39:3297-3302.
26. Ucar M., Neuvonen M., Luurila H., Dahlqvist R., Neuvonen P.J., Mjörndal T. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur. J. Clin. Pharmacol. 2004, 59:879-882.
27. Xu C., Li C.Y., Kong A.N. Induction of Phase I, II, III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 2005, 28:249-269.